open access
Long-term remission of corticosteroid-resistant Graves’ orbitopathy after therapy with tocilizumab
Affiliations- Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
- Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland
open access
Abstract
Not required for Clinical Vignettes.
Abstract
Not required for Clinical Vignettes.
Keywords
Graves’ orbitopathy; tocilizumab
About this articleTitle
Long-term remission of corticosteroid-resistant Graves’ orbitopathy after therapy with tocilizumab
Journal
Issue
Article type
Clinical vignette
Pages
117-118
Published online
2024-02-21
Page views
367
Article views/downloads
303
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2024;75(1):117-118.
Keywords
Graves’ orbitopathy
tocilizumab
Authors
Joanna Rymuza
Aleksander Kuś
Dorota Białas-Niedziela
Monika Turczyńska
Dariusz Kęcik
Tomasz Bednarczuk
References (6)- Bartalena L, Kahaly GJ, Baldeschi L, et al. EUGOGO † . The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021; 185(4): G43–G67.
- Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022; 11(6).
- Nowak M, Marek B, Kos-Kudła B, et al. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)]. Endokrynol Pol. 2022; 73(4): 756–777.
- Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Tocilizumab in Graves Orbitopathy Study Group. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018; 195: 181–190.
- Dorado Cortez O, Grivet D, Perrillat N, et al. Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study. Orbit. 2023; 42(4): 411–417.
- Moi L, Hamedani M, Ribi C. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab. Clin Endocrinol (Oxf). 2022; 97(3): 363–370.
